Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Phenotypic Discordance in Siblings with Identical Compound Heterozygous PARK2 Mutations.

Isaacs D, Claassen D, Bowman AB, Hedera P.

Brain Sci. 2017 Jun 24;7(7). pii: E71. doi: 10.3390/brainsci7070071.

2.

The Monoamine Brainstem Reticular Formation as a Paradigm for Re-Defining Various Phenotypes of Parkinson's Disease Owing Genetic and Anatomical Specificity.

Gambardella S, Ferese R, Biagioni F, Busceti CL, Campopiano R, Griguoli AMP, Limanaqi F, Novelli G, Storto M, Fornai F.

Front Cell Neurosci. 2017 Apr 18;11:102. doi: 10.3389/fncel.2017.00102. eCollection 2017. Review.

3.

Nonmotor symptoms in patients with Parkinson disease: A cross-sectional observational study.

Zhang TM, Yu SY, Guo P, Du Y, Hu Y, Piao YS, Zuo LJ, Lian TH, Wang RD, Yu QJ, Jin Z, Zhang W.

Medicine (Baltimore). 2016 Dec;95(50):e5400.

4.

Versatile members of the DNAJ family show Hsp70 dependent anti-aggregation activity on RING1 mutant parkin C289G.

Kakkar V, Kuiper EF, Pandey A, Braakman I, Kampinga HH.

Sci Rep. 2016 Oct 7;6:34830. doi: 10.1038/srep34830.

5.

Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance.

Hernandez DG, Reed X, Singleton AB.

J Neurochem. 2016 Oct;139 Suppl 1:59-74. doi: 10.1111/jnc.13593. Epub 2016 Apr 18. Review.

6.

Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD).

Zhou ZD, Sathiyamoorthy S, Angeles DC, Tan EK.

Mol Brain. 2016 Apr 18;9:41. doi: 10.1186/s13041-016-0218-2. Review.

7.

Analysis of PRKN Variants and Clinical Features in Polish Patients with Parkinson's Disease.

Oczkowska A, Florczak-Wyspianska J, Permoda-Osip A, Owecki M, Lianeri M, Kozubski W, Dorszewska J.

Curr Genomics. 2015 Aug;16(4):215-23. doi: 10.2174/1389202916666150326002549.

8.

Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose.

Li J, Li S, Zhang L, Ouyang L, Liu B.

Oncotarget. 2015 Dec 1;6(38):40480-95. doi: 10.18632/oncotarget.5803. Review.

9.

A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Cornejo-Olivas MR, Torres L, Mata IF, Mazzetti P, Rivas D, Cosentino C, Inca-Martinez M, Cuba JM, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 May;21(5):444-8. doi: 10.1016/j.parkreldis.2015.01.005. Epub 2015 Jan 15.

10.

Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications.

Cenci MA.

Front Neurol. 2014 Dec 15;5:242. doi: 10.3389/fneur.2014.00242. eCollection 2014. Review.

11.

The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study.

Sharp ME, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella C, Nance M, Bressman S, Scott WK, Tanner C, Waters C, Fahn S, Cote L, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Payami H, Molho E, Factor SA, Nutt J, Serrano C, Arroyo M, Pauciulo MW, Nichols WC, Clark LN, Alcalay RN, Marder KS.

Mov Disord. 2015 Feb;30(2):278-83. doi: 10.1002/mds.26065. Epub 2014 Nov 12.

12.

PARK2 patient neuroprogenitors show increased mitochondrial sensitivity to copper.

Aboud AA, Tidball AM, Kumar KK, Neely MD, Han B, Ess KC, Hong CC, Erikson KM, Hedera P, Bowman AB.

Neurobiol Dis. 2015 Jan;73:204-12. doi: 10.1016/j.nbd.2014.10.002. Epub 2014 Oct 12.

13.

Parkin (PARK 2) mutations are rare in Czech patients with early-onset Parkinson's disease.

Fiala O, Zahorakova D, Pospisilova L, Kucerova J, Matejckova M, Martasek P, Roth J, Ruzicka E.

PLoS One. 2014 Sep 19;9(9):e107585. doi: 10.1371/journal.pone.0107585. eCollection 2014.

14.

Cerebellum in levodopa-induced dyskinesias: the unusual suspect in the motor network.

Kishore A, Popa T.

Front Neurol. 2014 Aug 18;5:157. doi: 10.3389/fneur.2014.00157. eCollection 2014. Review.

15.

Genetic diagnosis of two dopa-responsive dystonia families by exome sequencing.

Sun ZF, Zhang YH, Guo JF, Sun QY, Mei JP, Zhou HL, Guan LP, Tian JY, Hu ZM, Li JD, Xia K, Yan XX, Tang BS.

PLoS One. 2014 Sep 2;9(9):e106388. doi: 10.1371/journal.pone.0106388. eCollection 2014.

16.

Ubiquitin pathways in neurodegenerative disease.

Atkin G, Paulson H.

Front Mol Neurosci. 2014 Jul 8;7:63. doi: 10.3389/fnmol.2014.00063. eCollection 2014. Review.

17.

HSPA1A-independent suppression of PARK2 C289G protein aggregation by human small heat shock proteins.

Minoia M, Grit C, Kampinga HH.

Mol Cell Biol. 2014 Oct 1;34(19):3570-8. doi: 10.1128/MCB.00698-14. Epub 2014 Jul 14.

18.

Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65.

Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M, Muqit MM.

Biochem J. 2014 May 15;460(1):127-39. doi: 10.1042/BJ20140334.

19.

Phosphorylation of Parkin at Serine65 is essential for activation: elaboration of a Miro1 substrate-based assay of Parkin E3 ligase activity.

Kazlauskaite A, Kelly V, Johnson C, Baillie C, Hastie CJ, Peggie M, Macartney T, Woodroof HI, Alessi DR, Pedrioli PG, Muqit MM.

Open Biol. 2014 Mar 19;4:130213. doi: 10.1098/rsob.130213.

20.

Cognitive and motor function in long-duration PARKIN-associated Parkinson disease.

Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, Ruiz D, Louis ED, Comella CL, Nance MA, Bressman SB, Scott WK, Tanner CM, Mickel SF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak KE, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Payami H, Molho E, Factor SA, Nutt JG, Serrano C, Arroyo M, Ottman R, Pauciulo MW, Nichols WC, Clark LN, Marder KS.

JAMA Neurol. 2014 Jan;71(1):62-7. doi: 10.1001/jamaneurol.2013.4498.

Supplemental Content

Support Center